[{"address1": "3160 Porter Drive", "address2": "Suite 250", "city": "Palo Alto", "state": "CA", "zip": "94304", "country": "United States", "phone": "650 391 9740", "website": "https://bridgebio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.", "fullTimeEmployees": 550, "companyOfficers": [{"maxAge": 1, "name": "Dr. Neil  Kumar Ph.D.", "age": 44, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1979, "fiscalYear": 2023, "totalPay": 1534840, "exercisedValue": 0, "unexercisedValue": 51135260}, {"maxAge": 1, "name": "Dr. Charles J. Homcy M.D.", "age": 75, "title": "Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director", "yearBorn": 1948, "fiscalYear": 2023, "totalPay": 563200, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Frank P. McCormick Ph.D.", "age": 73, "title": "Co-Founder, Chairman of Oncology & Director", "yearBorn": 1950, "fiscalYear": 2023, "totalPay": 542778, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Brian C. Stephenson C.F.A., Ph.D.", "age": 42, "title": "CFO & Secretary", "yearBorn": 1981, "fiscalYear": 2023, "totalPay": 1151240, "exercisedValue": 0, "unexercisedValue": 16193392}, {"maxAge": 1, "name": "Dr. Richard H. Scheller Ph.D.", "age": 70, "title": "Chairman of Research & Development", "yearBorn": 1953, "fiscalYear": 2023, "totalPay": 509622, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Uma  Sinha Ph.D.", "age": 65, "title": "Chief Scientific Officer", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 1313457, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Grace  Rauh", "title": "Vice President of Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Eli M. Wallace Ph.D.", "age": 56, "title": "Chief Scientific Officer of Oncology", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Thomas  Trimarchi Ph.D.", "title": "Chief Product Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Eric Michael David J.D., M.D., Ph.D.", "age": 51, "title": "Chief Executive Officer of Gene Therapy", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 10, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1719619200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 25.2, "open": 25.48, "dayLow": 24.66, "dayHigh": 26.0, "regularMarketPreviousClose": 25.2, "regularMarketOpen": 25.48, "regularMarketDayLow": 24.66, "regularMarketDayHigh": 26.0, "beta": 1.082, "forwardPE": -8.645051, "volume": 7407595, "regularMarketVolume": 7407595, "averageVolume": 1967966, "averageVolume10days": 4082720, "averageDailyVolume10Day": 4082720, "bid": 25.31, "ask": 25.4, "bidSize": 900, "askSize": 1100, "marketCap": 4739977216, "fiftyTwoWeekLow": 16.61, "fiftyTwoWeekHigh": 44.32, "priceToSalesTrailing12Months": 21.683634, "fiftyDayAverage": 27.2604, "twoHundredDayAverage": 30.241224, "currency": "USD", "enterpriseValue": 5961736192, "profitMargins": -2.46235, "floatShares": 121209236, "sharesOutstanding": 187128992, "sharesShort": 16661668, "sharesShortPriorMonth": 15782439, "sharesShortPreviousMonthDate": 1715731200, "dateShortInterest": 1718323200, "sharesPercentSharesOut": 0.088999994, "heldPercentInsiders": 0.05238, "heldPercentInstitutions": 0.9496, "shortRatio": 9.97, "shortPercentOfFloat": 0.1374, "impliedSharesOutstanding": 187128992, "bookValue": -5.609, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -538262016, "trailingEps": -3.23, "forwardEps": -2.93, "pegRatio": -0.15, "enterpriseToRevenue": 27.273, "enterpriseToEbitda": -12.781, "52WeekChange": 0.45994234, "SandP52WeekChange": 0.22553468, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "BBIO", "underlyingSymbol": "BBIO", "shortName": "BridgeBio Pharma, Inc.", "longName": "BridgeBio Pharma, Inc.", "firstTradeDateEpochUtc": 1561642200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "d3adccf0-6693-305c-9651-8da79033d61c", "messageBoardId": "finmb_412911458", "gmtOffSetMilliseconds": -14400000, "currentPrice": 25.33, "targetHighPrice": 70.0, "targetLowPrice": 37.0, "targetMeanPrice": 49.75, "targetMedianPrice": 48.5, "recommendationMean": 1.9, "recommendationKey": "buy", "numberOfAnalystOpinions": 12, "totalCash": 519691008, "totalCashPerShare": 2.777, "ebitda": -466449984, "totalDebt": 1728772992, "quickRatio": 5.338, "currentRatio": 5.537, "totalRevenue": 218596992, "revenuePerShare": 1.291, "returnOnAssets": -0.40077, "freeCashflow": -382719264, "operatingCashflow": -602934976, "revenueGrowth": 114.619, "grossMargins": 0.98905, "ebitdaMargins": -2.13384, "operatingMargins": 0.01773, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-30"}]